124 related articles for article (PubMed ID: 34412001)
21. Is neuron-specific enolase useful for diagnosing malignant pleural effusions? evidence from a validation study and meta-analysis.
Zhu J; Feng M; Liang L; Zeng N; Wan C; Yang T; Shen Y; Wen F
BMC Cancer; 2017 Aug; 17(1):590. PubMed ID: 28854885
[TBL] [Abstract][Full Text] [Related]
22. Clinical Value of Tumor Markers for Determining Cause of Pleural Effusion.
Gu Y; Zhai K; Shi HZ
Chin Med J (Engl); 2016 Feb; 129(3):253-8. PubMed ID: 26831224
[TBL] [Abstract][Full Text] [Related]
23. A retrospective study on the combined biomarkers and ratios in serum and pleural fluid to distinguish the multiple types of pleural effusion.
Lin L; Li S; Xiong Q; Wang H
BMC Pulm Med; 2021 Mar; 21(1):95. PubMed ID: 33740937
[TBL] [Abstract][Full Text] [Related]
24. Clinical utility of pleural fluid YKL-40 as a marker of malignant pleural effusion.
Javath Hussain S; Selvaraj J; Mohanty Mohapatra M; Rajendiran S
Curr Probl Cancer; 2019 Aug; 43(4):354-362. PubMed ID: 30471784
[TBL] [Abstract][Full Text] [Related]
25. Differential diagnosis of tuberculous and malignant pleural effusions: comparison of the Th1/Th2 cytokine panel, tumor marker panel and chemistry panel.
Zhang J; Chen Y; He G; Jiang X; Chen P; Ouyang J
Scand J Clin Lab Invest; 2020 Jul; 80(4):265-270. PubMed ID: 32108543
[TBL] [Abstract][Full Text] [Related]
26. Elevated Hsp90-beta contributes to differential diagnosis of pleural effusion caused by lung cancer and correlates with malignant biological behavior of lung cancer.
Biaoxue R; Min L; Tian F; Wenlong G; Hua L
BMC Pulm Med; 2018 Dec; 18(1):188. PubMed ID: 30522463
[TBL] [Abstract][Full Text] [Related]
27. Laboratory Discrimination Between Neutrophilic Malignant and Parapneumonic Pleural Effusions.
Lee J; Lee YH; Seo H; Lee H; Kim YK; Yoo SS; Lee SY; Cha SI; Park JY; Kim CH
Am J Med Sci; 2019 Aug; 358(2):115-120. PubMed ID: 31331448
[TBL] [Abstract][Full Text] [Related]
28. Predicting malignant and tuberculous pleural effusions through demographics and pleural fluid analysis of patients.
Valdés L; San-José E; Ferreiro L; Golpe A; González-Barcala FJ; Toubes ME; Rodríguez-Álvarez MX; Álvarez-Dobaño JM; Rodríguez-Núñez N; Rábade C; Gude F
Clin Respir J; 2015 Apr; 9(2):203-13. PubMed ID: 25849297
[TBL] [Abstract][Full Text] [Related]
29. The comparison of pleural fluid TNF-alpha and IL-10 levels with ADA in tuberculous pleural effusion.
Ciledag A; Kaya A; Erol S; Sen E; Celik G; Cesur S; Fidan Y; Kinikli S
Curr Med Chem; 2010; 17(19):2096-100. PubMed ID: 20423308
[TBL] [Abstract][Full Text] [Related]
30. Clinical value of jointly detection pleural fluid Midkine, pleural fluid adenosine deaminase, and pleural fluid carbohydrate antigen 125 in the identification of nonsmall cell lung cancer-associated malignant pleural effusion.
Zhang F; Wang J; Zheng X; Hu L; Chen J; Jiang F; Wang Y
J Clin Lab Anal; 2018 Oct; 32(8):e22576. PubMed ID: 29797475
[TBL] [Abstract][Full Text] [Related]
31. Diagnostic utility of LUNX mRNA and VEGF mRNA in pleural fluid for differentiating benign from malignant origin.
Bao QL; Li J; Sun W; Jiang HG; Zhu LR; Wang Y
Jpn J Clin Oncol; 2014 Dec; 44(12):1198-205. PubMed ID: 25425729
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic accuracy of endostatin for malignant pleural effusion: A clinical study and meta-analysis.
Tian P; Shen Y; Feng M; Zhu J; Song H; Wan C; Chen L; Wen F
Postgrad Med; 2015 Jun; 127(5):529-34. PubMed ID: 25979108
[TBL] [Abstract][Full Text] [Related]
33. Identification and diagnostic value of pleural fluid periostin and serum periostin of malignant pleural effusions in patients with non-small-cell lung cancer.
Wang J; Fu J; Shen Q; Zhang F; Wang Y; Wu LL
J Clin Lab Anal; 2019 Sep; 33(7):e22943. PubMed ID: 31268191
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic and prognostic values of endothelial-cell-specific molecule-1 with malignant pleural effusions in patients with non-small cell lung cancer.
Lu GJ; Shao CJ; Zhang Y; Wei YY; Xie WP; Kong H
Oncotarget; 2017 Jul; 8(30):49217-49223. PubMed ID: 28514746
[TBL] [Abstract][Full Text] [Related]
35. Combining clinical and analytical parameters improves prediction of malignant pleural effusion.
Valdés L; San-José E; Ferreiro L; González-Barcala FJ; Golpe A; Álvarez-Dobaño JM; Toubes ME; Rodríguez-Núñez N; Rábade C; Lama A; Gude F
Lung; 2013 Dec; 191(6):633-43. PubMed ID: 24085319
[TBL] [Abstract][Full Text] [Related]
36. Identification of differentially expressed miRNAs in differentiating benign from malignant pleural effusion.
Bao Q; Xu Y; Ding M; Chen P
Hereditas; 2020 Feb; 157(1):6. PubMed ID: 32102688
[TBL] [Abstract][Full Text] [Related]
37. Pro-cathepsin D as a diagnostic marker in differentiating malignant from benign pleural effusion: a retrospective cohort study.
Choi H; Ko Y; Lee CY
BMC Cancer; 2020 Aug; 20(1):825. PubMed ID: 32867726
[TBL] [Abstract][Full Text] [Related]
38. The pleural fluid lactate dehydrogenase/adenosine deaminase ratio differentiates between tuberculous and parapneumonic pleural effusions.
Wang J; Liu J; Xie X; Shen P; He J; Zeng Y
BMC Pulm Med; 2017 Dec; 17(1):168. PubMed ID: 29202740
[TBL] [Abstract][Full Text] [Related]
39. The diagnostic ability of high-fluorescent cells combined with carcinoembryonic antigen for malignant pleural effusion.
Wu W; Zhao C; Shen T; Tong X; Chen W
Int J Lab Hematol; 2019 Aug; 41(4):509-512. PubMed ID: 31018036
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic value of survivin for malignant pleural effusion: a clinical study and meta-analysis.
Tian P; Shen Y; Wan C; Yang T; An J; Yi Q; Chen L; Wang T; Wang Y; Wen F
Int J Clin Exp Pathol; 2014; 7(9):5880-7. PubMed ID: 25337230
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
